covid
Endocrinología y Nutrición (English Edition) Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with...
Journal Information

Statistics

Follow this link to access the full text of the article

Original article
Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus
Coste-efectividad de exenatida en comparación con insulina glargina en pacientes con obesidad y diabetes mellitus tipo 2 en España
Gordon Goodalla, María Costib, Louise Timlinc, Jesús Reviriegod, José Antonio Sacristánd, Jayne Smith-Palmera, Tatiana Dillab,
Corresponding author
dilla_tatiana@lilly.com

Corresponding author.
a IMS Health, Basilea, Switzerland
b Unidad de Investigación de Resultados Sanitarios, Eli Lilly, Alcobendas, Madrid, Spain
c European Outcomes Research, Eli Lilly, Windlesham, Surrey, United Kingdom
d Departamento Médico, Eli Lilly, Alcobendas, Madrid, Spain
Read
6666
Times
was read the article
1267
Total PDF
5399
Total HTML
Share statistics
Article information
ISSN: 21735093
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2025 12 17 1 18
2025 11 97 39 136
2025 10 112 35 147
2025 9 62 17 79
2025 8 48 12 60
2025 7 72 16 88
2025 6 51 9 60
2025 5 68 9 77
2025 4 76 9 85
2025 3 95 24 119
2025 2 71 5 76
2025 1 126 6 132
2024 12 38 6 44
2024 11 61 2 63
2024 10 75 9 84
2024 9 33 10 43
2024 8 39 14 53
2024 7 20 13 33
2024 6 16 3 19
2024 5 17 3 20
2024 4 29 12 41
2024 3 36 5 41
2024 2 17 4 21
2024 1 28 2 30
2023 12 23 8 31
2023 11 21 6 27
2023 10 47 11 58
2023 9 17 4 21
2023 8 30 8 38
2023 7 27 7 34
2023 6 24 4 28
2023 5 51 7 58
2023 4 50 8 58
2023 3 48 3 51
2023 2 35 10 45
2023 1 26 3 29
2022 12 22 4 26
2022 11 38 6 44
2022 10 38 7 45
2022 9 20 8 28
2022 8 22 12 34
2022 7 26 8 34
2022 6 16 9 25
2022 5 18 8 26
2022 4 17 9 26
2022 3 22 10 32
2022 2 31 7 38
2022 1 55 7 62
2021 12 20 13 33
2021 11 36 13 49
2021 10 75 17 92
2021 9 50 12 62
2021 8 66 8 74
2021 7 35 12 47
2021 6 28 18 46
2021 5 23 14 37
2021 4 39 15 54
2021 3 41 10 51
2021 2 37 6 43
2021 1 39 9 48
2020 12 47 12 59
2020 11 66 14 80
2020 10 44 6 50
2020 9 28 9 37
2020 8 41 7 48
2020 7 46 4 50
2020 6 26 5 31
2020 5 24 20 44
2020 4 21 18 39
2020 3 32 3 35
2020 2 29 17 46
2020 1 30 9 39
2019 12 25 7 32
2019 11 11 8 19
2019 10 21 4 25
2019 9 28 5 33
2019 8 17 0 17
2019 7 14 22 36
2019 6 43 19 62
2019 5 116 30 146
2019 4 49 4 53
2019 3 10 2 12
2019 2 21 2 23
2019 1 15 8 23
2018 12 19 5 24
2018 11 29 3 32
2018 10 14 4 18
2018 9 36 11 47
2018 8 10 5 15
2018 7 16 10 26
2018 6 14 3 17
2018 5 23 10 33
2018 4 15 11 26
2018 3 20 3 23
2018 2 15 4 19
2018 1 24 3 27
2017 12 26 8 34
2017 11 20 5 25
2017 10 18 3 21
2017 9 23 7 30
2017 8 21 5 26
2017 7 25 4 29
2017 6 40 4 44
2017 5 46 5 51
2017 4 61 2 63
2017 3 55 26 81
2017 2 48 3 51
2017 1 18 2 20
2016 12 32 7 39
2016 11 41 6 47
2016 10 66 5 71
2016 9 47 11 58
2016 8 32 3 35
2016 7 37 6 43
2016 6 30 19 49
2016 5 40 16 56
2016 4 31 12 43
2016 3 33 17 50
2016 2 42 20 62
2016 1 35 10 45
2015 12 30 14 44
2015 11 53 6 59
2015 10 39 8 47
2015 9 36 9 45
2015 8 31 6 37
2015 7 21 8 29
2015 6 15 1 16
2015 5 25 4 29
2015 4 34 13 47
2015 3 21 6 27
2015 2 36 3 39
2015 1 38 9 47
2014 12 61 12 73
2014 11 32 2 34
2014 10 40 10 50
2014 9 40 4 44
2014 8 29 3 32
2014 7 47 12 59
2014 6 26 2 28
2014 5 31 5 36
2014 4 42 1 43
2014 3 35 7 42
2014 2 10 0 10
2014 1 16 5 21
2013 12 25 4 29
2013 11 38 3 41
2013 10 41 5 46
2013 9 40 3 43
2013 8 44 3 47
Show all

Follow this link to access the full text of the article